SiSaf Strengthens it’s Leadership Team

SiSaf Strengthens it’s Leadership Team to Control its Rapid Growth Phase – Richard Scarrott Joins SiSaf Ltd as Chief Financial Officer

London, UK. August 19th 2019 SiSaf Ltd, pioneers of Bio-Courier® technology, today announced the appointment of Richard Scarrott as Chief Financial Officer (CFO).

Richard will report to SiSaf’s Chief Executive Officer, Dr Suzanne Saffie-Seibert, and oversee SiSafs global finance organization.  He will serve on SiSaf’s Leadership Committee and be based in the Group’s UK headquarters in Guilford Surrey.

Richard has 30 years of financial management, corporate finance and commercial experience. At Norwood Immunology, Richard was responsible for the company’s overall financial and strategy.  As CFO, Richard oversaw corporate finance, cash management, financial planning and analysis, tax, accounting systems and controls, investor relations, internal audit and risk management and was responsible for corporate strategy and planning.  Managing international activity across Europe, Australia and the USA.  He successfully completed the process of a public listing Norwood Immunology on AIM with an associated fund-raising and then led further funding and acquisitions.

Richard has also spent 10 years as Finance and Commercial Director of a branded UK consumer logistics business in a role covering finance, commercial, strategy, HR, and operations and was fundamental to helping the company grow, develop and professionalise.  Implementing change to people, systems, processes and business strategy, along with cash and performance management.  Challenging the business to create and implement the business strategy to improve performance and drive value.  Managing the relationships with finance providers, shareholders and banks to deliver stringent cash control and when required raise new finance.

Richard qualified at Arthur Andersen and worked for 5 years in Restructuring and Turnaround and then 7 years in Corporate Finance Advisory leading M&A and fundraising engagement teams, latterly as a Director of the London Healthcare team.  Richard is a Fellow Chartered Accountant and received his bachelor’s degree in Business Management.

“I couldn’t be more thrilled to welcome Richard to SiSaf where he will undoubtedly make an immediate impact as we enter a significant growth phase for the company” said Dr Suzanne Saffie-Seibert PhD founder and CEO of SiSaf. ” Richard is a great addition to our leadership team and will help us execute our long-term vision to unlock the full power of precision medicine with our Bio-Courier® technology.  His wealth of investment, corporate finance and deal execution experience will be a tremendous asset as we continue to develop and commercialize our revolutionary portfolio”


“I can’t imagine a more exciting time to join SiSaf and make an impact” Richard said. “the potential of Bio-Courier technology in multiple industries is extraordinary but in particular SiSaf’s opportunity to transform the delivery of gene therapy is truly ground-breaking and extremely valuable to both patients and investors.

About SiSaf

SiSaf are pioneers of silicon-based Bio-courier technology that leverages the unique properties of elemental silicon (14Si) to overcome the limitations of current drug technologies. Built upon a decade of research and patented technological innovation, SiSaf’s platform is changing the way therapeutic molecules target disease helping to make tomorrow’s precision medicines a reality. SiSaf is a commercial stage biopharmaceutical company headquartered in Guilford, UK, with fully integrated state-of-the-art research labs, manufacturing and bio-analytical facilities to fast track development. To learn more, please visit

 About Bio-Courier® Technology

SiSaf’s first-to-market Bio-Courier platform technology leverages the unique properties of bioabsorbable silicon, lipids and amino acids to address the significant challenges of stability, solubility, targeting and controlled release of complex therapeutic molecules.

Its customizable design and fabrication provide unparalleled flexibility with respect to therapeutic molecule type and target cell location. Bio-Couriers degrade to the bioavailable form of silicon, eliminating the accumulation of potentially toxic or immune-activating material and supporting cell health. Cost-effective, scaled manufacturing provides unequaled capacity to address both rare diseases and large patient populations.